Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

[This corrects the article DOI: 10.3389/fendo.2021.779365.].

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in endocrinology (Lausanne) 2021-12, Vol.12, p.830469-830469
Hauptverfasser: Sun, Chengjun, Lu, Biao, Liu, Yu, Zhang, Yaqin, Wei, Haiyan, Hu, Xu, Hu, Pei, Zhao, Qian, Liu, Yanling, Ye, Kan, Wang, Kan, Gu, Zaiyan, Liu, Zheng, Ye, Jin, Zhang, Hongxiao, Zhu, Hong, Jiang, Zhihong, Liu, Yanjie, Wan, Naijun, Yan, Chengming, Yin, Jianying, Ying, Lirong, Huang, Feng, Yin, Qingjin, Xi, Li, Luo, Feihong, Cheng, Ruoqian
Format: Artikel
Sprache:eng
Schlagworte:
children
Endocrinology
growth hormone deficiency
IGF-2
PEG-rhGH
PEGylated recombinant human growth hormone
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[This corrects the article DOI: 10.3389/fendo.2021.779365.].
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2021.830469